NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Want to cut your energy bills? Here’s how five experts are doing it 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
WALTHAM, Mass., March 01, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences:
- Cowen and Company Annual Health Care Conference
Monday, March 6, 2017 at 2:40 p.m. ET
Location: Boston, MA
- Raymond James Annual Institutional Investors Conference
Wednesday, March 8, 2017 at 10:25 a.m. ET
Location: Orlando, FL
- Barclays Global Healthcare Conference
Tuesday, March 14, 2017 at 2:35 p.m. ET
Location: Miami, FL
To access the live webcasts, please visit the Investors section of the company’s website at www.amagpharma.com. A replay of each event will be archived on the site for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of women's health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals Contact: Christi Waarich Associate Director, Investor Relations 617-498-7638
